Service d'Hématologie Clinique, CHU de Nantes, France.
Hum Immunol. 2012 Jul;73(7):711-4. doi: 10.1016/j.humimm.2012.03.013. Epub 2012 Apr 12.
The impact of HLA-DPB1 mismatches after unrelated hematopoietic stem cell transplantation (HSCT) remains controversial. We retrospectively analyzed the impact of permissive/non-permissive HLA-DPB1 mismatches on the outcome of 141 patients who underwent 10/10 HLA allelic-matched unrelated HSCT. Each pair was classified according to the 3 (TCE3) and 4-group (TCE4) algorithm based on DPB1 alleles immunogenicity. Outcome analysis revealed that TCE3 and TCE4 non-permissive HLA-DPB1 disparities were not associated with worsened overall survival, relapse risk neither risk of acute GvHD. Overall, this single center retrospective study does not confirm the adverse prognostic of non-permissive HLA-DPB1 mismatches.
在无关造血干细胞移植（HSCT）后，HLA-DPB1 错配的影响仍存在争议。我们回顾性分析了 141 例接受 10/10 HLA 等位基因匹配的无关 HSCT 的患者中，允许性/非允许性 HLA-DPB1 错配对其结果的影响。根据 DPB1 等位基因免疫原性，每对根据 3（TCE3）和 4 组（TCE4）算法进行分类。结果分析表明，TCE3 和 TCE4 非允许性 HLA-DPB1 差异与总生存率、复发风险或急性移植物抗宿主病风险的恶化无关。总的来说，这项单中心回顾性研究并不能证实非允许性 HLA-DPB1 错配的不良预后。
